222 related articles for article (PubMed ID: 29433973)
21. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
[TBL] [Abstract][Full Text] [Related]
22. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.
Tosoian JJ; Loeb S; Feng Z; Isharwal S; Landis P; Elliot DJ; Veltri R; Epstein JI; Partin AW; Carter HB; Trock B; Sokoll LJ
J Urol; 2012 Oct; 188(4):1131-6. PubMed ID: 22901577
[TBL] [Abstract][Full Text] [Related]
23. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
24. Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.
Patel HD; Feng Z; Landis P; Trock BJ; Epstein JI; Carter HB
J Urol; 2014 Mar; 191(3):629-37. PubMed ID: 24060641
[TBL] [Abstract][Full Text] [Related]
25. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance.
Ganesan V; Dai C; Nyame YA; Greene DJ; Almassi N; Hettel D; Zabell J; Arora H; Haywood S; Crane A; Reichard C; Zampini A; Elshafei A; Stein RJ; Fareed K; Jones JS; Gong M; Stephenson AJ; Klein EA; Berglund RK
Urology; 2017 Sep; 107():184-189. PubMed ID: 28625591
[TBL] [Abstract][Full Text] [Related]
27. Using Competing Risk of Mortality to Inform the Transition from Prostate Cancer Active Surveillance to Watchful Waiting.
Huang MM; Alam R; Gabrielson AT; Su ZT; Kassiri B; Fletcher SA; Biles MJ; Patel HD; Pavlovich CP; Schwen ZR
Eur Urol Focus; 2022 Sep; 8(5):1141-1150. PubMed ID: 34344628
[TBL] [Abstract][Full Text] [Related]
28. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
Newcomb LF; Thompson IM; Boyer HD; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Ellis WJ; Fazli L; Feng Z; Gleave ME; Kunju P; Lance RS; McKenney JK; Meng MV; Nicolas MM; Sanda MG; Simko J; So A; Tretiakova MS; Troyer DA; True LD; Vakar-Lopez F; Virgin J; Wagner AA; Wei JT; Zheng Y; Nelson PS; Lin DW;
J Urol; 2016 Feb; 195(2):313-20. PubMed ID: 26327354
[TBL] [Abstract][Full Text] [Related]
30. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
[TBL] [Abstract][Full Text] [Related]
31. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
Newcomb LF; Zheng Y; Faino AV; Bianchi-Frias D; Cooperberg MR; Brown MD; Brooks JD; Dash A; Fabrizio MD; Gleave ME; Liss M; Morgan TM; Thompson IM; Wagner AA; Carroll PR; Nelson PS; Lin DW
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):438-445. PubMed ID: 30664734
[TBL] [Abstract][Full Text] [Related]
32. Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
Shah S; Beckmann K; Van Hemelrijck M; Challacombe B; Popert R; Dasgupta P; Rusere J; Zisengwe G; Elhage O; Santaolalla A
BMC Cancer; 2021 May; 21(1):573. PubMed ID: 34011308
[TBL] [Abstract][Full Text] [Related]
33. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
Willemse PM; Davis NF; Grivas N; Zattoni F; Lardas M; Briers E; Cumberbatch MG; De Santis M; Dell'Oglio P; Donaldson JF; Fossati N; Gandaglia G; Gillessen S; Grummet JP; Henry AM; Liew M; MacLennan S; Mason MD; Moris L; Plass K; O'Hanlon S; Omar MI; Oprea-Lager DE; Pang KH; Paterson CC; Ploussard G; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; Van den Broeck T; van der Kwast TH; van der Poel HG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TBL
Eur Urol; 2022 Apr; 81(4):337-346. PubMed ID: 34980492
[TBL] [Abstract][Full Text] [Related]
34. Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance.
Reese AC; Feng Z; Landis P; Trock BJ; Epstein JI; Carter HB
Urology; 2015 Nov; 86(5):991-5. PubMed ID: 26335496
[TBL] [Abstract][Full Text] [Related]
35. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
[TBL] [Abstract][Full Text] [Related]
36. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
[TBL] [Abstract][Full Text] [Related]
37. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
Druskin SC; Mamawala M; Tosoian JJ; Epstein JI; Pavlovich CP; Carter HB; Trock BJ
J Urol; 2019 Jan; 201(1):98-104. PubMed ID: 30114397
[TBL] [Abstract][Full Text] [Related]
38. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
[TBL] [Abstract][Full Text] [Related]
39. Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer.
Baraban E; Erak E; Fatima A; Akbari A; Zhao J; Fletcher SA; Bhanji Y; de la Calle CM; Mamawala M; Landis P; Macura KJ; Pavlovich CP; Epstein JI
J Urol; 2023 Jul; 210(1):99-107. PubMed ID: 37042826
[TBL] [Abstract][Full Text] [Related]
40. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
